Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468934 | 0.83 | CYP1A2 (0.46) | CYP2C19ACACBLMNAMEN1KMT2A | |
| SCHEMBL27545848 | 0.82 | ALDH1A1 (0.48) | CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL8950594 | 0.80 | ALDH1A1 (0.39) | LMNAKMT2AALDH1A1HPGDMAPT | |
| SCHEMBL18657152 | 0.78 | MAPK1 (0.45) | CYP2D6CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL13686083 | 0.76 | HPGD (0.43) | ACACBKMT2AALDH1A1RAB9AHPGD | |
| SCHEMBL12016065 | 0.76 | LMNA (0.46) | CYP2D6CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL11111466 | 0.75 | ALDH1A1 (0.41) | ACACBLMNAMEN1KMT2ACHRM2 | |
| SCHEMBL11111469 | 0.75 | ALDH1A1 (0.41) | ACACBLMNAMEN1KMT2ACHRM2 | |
| SCHEMBL10362542 | 0.75 | LMNA (0.49) | LMNAMEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL8889185 | 0.75 | ALOX5 (0.40) | CYP2D6ACACBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919857-B1 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-8129560-B2 | Process for the synthesis of mandipropamid and derivatives thereof | SYNGENTA CROP PROTECTION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090118532-A1 | Process for the Synthesis of Mandipropamid and Derivatives Thereof | SYNGENTA CROP PROTECTION, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1919857-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | Syngeta Participations AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020381-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118532-A1 | Process for the Synthesis of Mandipropamid and Derivatives Thereof | OPRM1, OPRD1, ADRA1D | CYP2D6 83/4885CYP2C19 101/4885ACACB 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.